BMS-582664 inhibits VEGF-stimulated and FGF-stimulated proliferating of HUVECs with IC50 of 40 nM and 276 nM. BMS-582664 (2 ¦ÌM) significantly inhibits VEGFR2, FGFR1, ERK1/2 and Akt phosphorylation in VEGF- and bFGF-stimulated SK-HEP1 cells and HepG-2 cells, while BMS-582664 alone has little effect on levels of phosphorylated ERK1/2, Akt, VEGFR2, and FGFR1 in nonstimulated cells. BMS-582664 inhibits CYP2C19, CYP3A4(BFC) and CYP3A4 (BzRes) with IC50 of 2.4 ¦ÌM, 0.51 ¦ÌM and 1.6 ¦ÌM, respectively. BMS-582664 exhibits high solid state stability (only 0.3% degradation at 50¡æ with desiccant over a period of 12 weeks) and acceptable solution state stability up to pH 6.5.

June 21, 2017

prudect name : BMS-582664 inhibits VEGF-stimulated and FGF-stimulated proliferating of HUVECs with IC50 of 40 nM and 276 nM. BMS-582664 (2 ¦ÌM) significantly inhibits VEGFR2, FGFR1, ERK1/2 and Akt phosphorylation in VEGF- and bFGF-stimulated SK-HEP1 cells and HepG-2 cells, while BMS-582664 alone has little effect on levels of phosphorylated ERK1/2, Akt, VEGFR2, and FGFR1 in nonstimulated cells. BMS-582664 inhibits CYP2C19, CYP3A4(BFC) and CYP3A4 (BzRes) with IC50 of 2.4 ¦ÌM, 0.51 ¦ÌM and 1.6 ¦ÌM, respectively. BMS-582664 exhibits high solid state stability (only 0.3% degradation at 50¡æ with desiccant over a period of 12 weeks) and acceptable solution state stability up to pH 6.5.
Brivanib alaninate (BMS-582664)

Synonyms: CAS NO: 649735-63-7Molecular Formula: C₂₂H₂₄FN₅O₄Molecular Weight: 441.46Purity: 98% minSolubility: In DMSOStorage: -20°C

174484-41-4 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18503082,15215425